Compare BridgeBio Pharma Inc (BBIO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ResMed Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while ResMed Inc. trades at $223.62 (market cap $32.61B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.17% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | RMD | |
|---|---|---|
Market Cap | $16.36B | $32.61B |
Sector | Health | Health |
52-Week High | $90.17 | $293.73 |
52-Week Low | $47.29 | $182.82 |
Enterprise Value | $18.14B | $31.97B |
Dividend Yield | — | 1.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
